Figure 8
Effect of native bevacizumab (Avastin), bevacizumab-loaded NP and unloaded NP on cell viability and proliferation of HUVEC cells. (A–C) MTT assay of HUVEC cells treated with 50 ng/mL of VEGF and different concentrations (0,1; 1; 10 and 100 µg/ml) of Bevacizumab, Bevacizumab-loaded NPs, or Unloaded NPs at different time points (24 h (A); 48 h (B) and 72 h (C)). (D) BrdU incorporation assay of HUVEC cells treated with 50 ng/mL VEGF and 10 µg/ml of Bevacizumab, Bevacizumab-loaded NPs, or Unloaded NPs for 72 h. In all graphs, bars represent mean values ± SD (n = 5–6 values per condition). One representative experiment out of three total is shown. *P < 0.05; **P < 0.01; and ***P < 0.001, determined as described in materials and methods.
